This tutorial will illustrate how to:

- Compare the survival rates in two groups
- Visualize the Kaplan-Meier survival curves
- Assess the impact of gene expression values on survival probabilities by Cox regression

Survival analysis is a branch of statistics which deals with modeling of time-toevent. In the context of "survival," the most common event studied is death although any other important biological event could be analyzed in a similar fashion (e.g., spreading of the primary tumor or occurrence/relapse of disease). It is important to emphasize that the significant event should be well-defined and occur at a specific time. As the primary outcome event is typically unfavorable (e.g., death, metastasis, relapse, etc.), the event is called a "hazard."

In the other words, survival analysis tries to answer questions such as: What is the proportion of a population who will survive past a certain time (i.e., what is the 5-year survival rate)? What is the rate at which the event occurs? Do particular characteristics of participants have an impact on survival rates (e.g., are certain genes associated with survival?? Is the 5-year survival rate improved in patients treated by a new drug?

An important feature of survival analysis is the presence of "censored" data. For instance, medical studies often focus on survival of patients after treatment so the survival times are recorded. At the end of the study period, some patients are still alive, some have died (and survival data should be available for those), and the fate of some patients is not known because they dropped out of the study. One possible reason for drop-out could be that the patient moved to a different geographical area, but it is also possible that the patient felt so much better that he felt that no further intervention is needed. Censored data represent the last group (study drop-outs or unknown status). The information from censored data is valuable because while it does not measure the actual survival time, it does measure a minimum length of survival to the time the study ends or the subject drops out of the study. Within the field of survival analysis, special tests are developed to correctly use both censored and uncensored observations. The details of the tests implemented in Partek[®] Genomics SuiteTM (PGS) could be found in the user's manual (available under **Help > User's Manual**).

Please note: The following tutorial was written using Partek[®] Genomics Suite[™] version 6.6. As PGS is a rapidly evolving software application, future versions of PGS may be different from the screenshots displayed in this tutorial. To ensure that

you are using the most current version of PGS, please visit **Help > Check for Updates.**

Tutorial Data Set

This example data set (236 samples) is a subset of fresh-frozen breast tumor specimens from a population-based cohort of 315 women with breast cancer. The clinicopathological characteristics accompanying each tumor include p53 status (mutant or wild-type), estrogen receptor (ER) status, progesterone receptor (PgR) status, lymph node status, tumor size, and patient age. Gene expression of all the samples was assessed on Affymetrix[®] U133A and U133B arrays (Miller LD *et al.*, GSE3494). Please note that Affymetrix data have been chosen for the illustration purposes only, and that the same functionality can be used to analyze data generated by any vendor.

The raw data files (.CEL) have already been imported into PGS; samples with no survival time data as well as sample attributes irrelevant for the survival analysis were removed, and the final spreadsheet was saved in PGS (*Survival_Tutorial.fmt* and *Survival_Tutorial.txt*). The files in a .zip folder are provided on Partek's tutorials page (under the *Gene Expression* tab) and are easily found by selecting **Help > On-line Tutorials** in the PGS main menu. To proceed with the exercise, download the .zip folder to your computer and unzip it.

To open the data file, use **File > Open...**, browse to the folder containing the tutorial data set, and select the file *Survival_Tutorial.fmt*. PGS will open the data spreadsheet where each row represents one tumor sample. Sample attributes are in columns 1 - 8, while columns 9+ are gene expression levels (probesets on columns) (Figure 1).

	Curre	nt Selection 8.5	Jection 8.5627												
		1. Survival (years)	2. Event	3. p53 status	4. ER status	5. PgR status	6. age at diagnosis	7. tumor size (mm)	8. Lymph node status	9. 1007_s_at	10. 1053_at	11. 117_at	12. 121_a		
L	1.	11.833	censored	wt	ER+	PgR-	68	9	LN-	11.3908	6.3384	7.34	9.607		
L	2.	11.833	censored	mutant	ER-	PgR-	40	12	LN-	11.3651	7.2669	7.9095	9.284		
1	3.	11.833	censored	mutant	ER+	PgR+	51	26	LN-	11.5778	7.337	7.4625	9.099		
L	4.	3.583	censored	mutant	ER+	PgR+	80	24	LN?	11.2411	6.9691	7.2639	9.336		
L	5.	11.75	censored	wt	ER+	PgR+	46	13	LN-	11.3729	6.7739	7.2534	9.106		
L	6.	11.333	censored	wt	ER+	PgR+	70	50	LN-	11.8454	6.6998	7.296	8.912		
L	7.	11.667	censored	mutant	ER+	PgR+	74	20	LN-	11.5412	7.319	7.1446	9.443		
H	8.	5.5	censored	wt	ER+	PgR+	38	32	LN-	11.5079	6.931	7.283	9.373		
L	9.	11.167	censored	wt	ER+	PgR+	67	12	LN+	11.4658	6.9128	7.4925	9.555		
	10.	7.417	censored	wt	ER-	PgR-	69	18	LN-	11.1284	6.5092	7.354	9.135		
	11.	11.583	censored	wt	ER+	PgR+	34	16	LN-	11.6635	6.9093	7.4456	9.206		
	12	11 167	concored	+	ED 1	DeD 1	70	10	LN	11 4442	6 7024	7 5107	0.264		

Figure 1: Viewing the sample data (one sample per row) for survival analysis

Kaplan-Meier Survival Curves

The Kaplan–Meier (KM) estimator shows the survival from study data when the incidence of disease is not constant over time. A plot of the KM estimate of the survival function, a KM curve, is a series of declining horizontal steps which approaches the true survival function for the original population when a large enough sample is taken. An important advantage of the KM curve is that it handles censored data which occur if a patient is lost to follow-up (drops out) before the final outcome is observed.

To perform survival analysis, at least two pieces of information (one column each) must be provided for each sample:

- Time-to-event: a numeric factor
- Whether the event has occurred or not or whether the time was censored: a categorical factor with two levels. Patients who participate in the full length of study and who do not experience the event are considered "censored"

Time-to-event indicates the time elapsed between the enrollment of a subject in the study and the occurrence of the primary outcome event. Traditionally, the occurrence of the event is coded as "1" (i.e., indicating the event occurred for a patient at the given time point), while the censored data (e.g. patient lost to follow-up or patient still alive at the end of the study) is coded by "0". Please note that PGS does not impose any limitation on the labels used for the two categories (do not have to be 0 and 1); in this tutorial, the events are coded as either death or censored. If a patient is still alive at the end of the study end. If a patient is lost to follow-up, then the time-to-event should indicate the period between enrollment and th

- To invoke the KM analysis, go to **Stat > Survival Analysis > Kaplan-Meier**
- In the present example (Figure 1), column #1 (*Survival (years)*) indicates the survival time of each patient (in years), while column #2 (*Event*) specifies the outcome for each patient: *death* or *censored*. Consequently, at the top of the *Kaplan-Meier* dialog box, set *Time Variable* to 1.
 Survival (years) and the *Event Variable* to 2. Event. Note that only variables with two categories are displayed in the *Event Variable* list, and only numeric data are displayed in the *Time Variable* pull-down list
- Select **death** from the *Event Status* drop-down list to indicate the primary outcome which automatically tell PGS that the censored outcome is coded as the other variable (in this example, *censored*)
- To test the difference in survival rates between the p53 mutants (*mutant*) and samples with wild-type p53 gene (*wt*), select **3. p53 status** in the *Candidates list* and click on the **Add Factor** > button to transfer it to the

Strata (Categorical) list (PGS will only accept categorical variables as strata). The dialog box should appear as in Figure 2

• Select **OK** to proceed

🧐 Kaplan-Meier o	of Spreadsheet 1		
Time Variable	1. Survival (years)		- 2
Event Variable	2. Event	✓ ② Event Status death	- 2
Candidate(s)		Test Variable(s) (Numeric) 🕐	
1. Survival (years) 2. Event 4. ER status 5. PgR status 6. age at diagnosis 7. tumor size (mm)		Add Factor > < Remove Factor	
8. Lymph node star	tus	Strata (Categorical) 🕐	
		Add Factor > 3. p53 status	
		OK Cancel	Apply

Figure 2: Configuring the Kaplan-Meier dialog

The KM plot will appear (Figure 3) displaying the survival curves for the p53 wildtype and p53 mutant groups. Each curve shows the survival probability at a given time point with censored outcomes indicated by triangles, and events (death in this tutorial) occurring wherever there is a downward step.



Figure 3: Kaplan-Meier plot comparing the survival curves between two groups. The horizontal axis indicates time to death; the vertical axis shows the cumulative proportion of survival. Censored events are symbolized by triangles; death occurs at each downward step in the plot

PGS performs two statistical tests to compare the survival curves: the log-rank test and the Wilcoxon-Gehan (Breslow's) test. Both tests work well with censored data. Low p-values indicate that the groups have significantly different survival times. See the legend for Figure 5.

In addition to the plot, a new spreadsheet (*KM*) is created (Figure 4).

	1. p53 status	2. Survival (years)	3. probability of Survival (years)	4. AtRisk	5. Dead	6. Censored	7. TotalDead	8. TotalAtRisk	9. In(KM)	10. ln(-ln(KM))
1.	mutant	0	0.981818	55	1	1	1	236	-0.0183491	-3.99817
2.	mutant	0.083	0.963293	53	1	1	1	234	-0.0373973	-3.28616
3.	mutant	0.167	0.963293	51	0	0	0	232	-0.0373973	-3.28616
4.	mutant	0.25	0.963293	51	0	0	1	231	-0.0373973	-3.28616
5.	mutant	0.333	0.944405	51	1	0	2	230	-0.0572	-2.8612
6.	mutant	0.417	0.944405	50	0	0	1	228	-0.0572	-2.8612
7.	mutant	0.583	0.944405	50	0	0	1	227	-0.0572	-2.8612
8.	mutant	0.833	0.944405	50	0	1	0	226	-0.0572	-2.8612
9.	mutant	0.917	0.944405	49	0	1	1	225	-0.0572	-2.8612
10.	mutant	1.083	0.92473	48	1	0	1	223	-0.0782534	-2.5478
11.	mutant	1.167	0.905055	47	1	0	2	222	-0.0997596	-2.30499

Figure 4: Viewing the KM spreadsheet, detailing the results of Kaplan-Meier survival analysis. Each row represents occurrence of at least one significant event

The spreadsheet is organized into two sections: the analysis of the p53 mutant group is followed by the p53 wild type group. Each row represents a time point at which at least one event occurred whereas the columns provide the following pieces of information:

- 1: Identifies the group membership (according to the strata)
- 2: Survival time corresponds to the entries in column #1 of the original (*Survival_Tutorial*) spreadsheet. At each given time, at least one event, either death or censored, was recorded
- 3: Probability of survival: cumulative probability of survival at a given time point (also known as KM survival estimate).
 (Cumulative probability is the probability of surviving all of the intervals before this time point.) As time increases, the cumulative survival probability decreases as events occur
- 4: Number of group members at risk (have not experienced the event). The count in each row is calculated by subtracting the number of deaths and censored events in the row above from the number at risk in the row above
- 5: Count of deaths at this time in the group
- 6: Count of censored events at the given time in the group
- 7: Total number of deaths in *all* groups at the given time
- 8: Total number of participants at risk in all groups. The count in each row is calculated by subtracting the number of deaths and censored events at the previous time point in both groups from the total number at risk at the previous time point
- 9: Natural logarithm of column #3; also noted as ln(KM)

10: Natural logarithm of the negative value of column #9, i.e., ln(-ln(KM)). A plot of ln(-ln(KM)) vs. ln(t) is often used to test the proportional hazards assumption. To visualize the risk, select this column and select View > Log Log S Plot (Figure 5)



Figure 5: Log Log S plot of KM data. As the lines are mostly parallel and do not cross, the log-rank test assumptions are valid. The Wilcoxon-Gehan test has more power if the lines had crossed or were not parallel but performs less well when there is extensive censored data

Cox Regression

The Kaplan-Meier method is useful for comparing survival curves in two or more groups with a primary exposure variable whereas the Cox regression (Cox proportional-hazards model) enables assessing the effect of several factors (predictors) on the outcome. Predictors that lower the probability of survival are called risk factors; protective factors are predictors that improve the survival probability. The Cox proportional-hazards model like similar to multiple logistic regression that considers time-to-event rather than simply whether an event occurred or not. Cox regression in PGS is accessed from the *Stat* menu.

- Select the Survival Tutorial spreadsheet in the spreadsheet navigator
- Select Stat > Survival Analysis > Cox Regression. The resulting dialog (Figure 6) resembles the Kaplan-Meier configuration dialog. Be sure to specify 1. Survival (years) for *Time Variable*, 2. Event for *Event Variable*, and death for *Event Status*. PGS will automatically select all the response variables (in this example: probesets) as *Predictor*.
- Optional *Co-predictor(s)* are numeric or categorical factors to be included in the regression model. To evaluate the association between tumor size and gene expression, select 7. tumor size (mm) in the list of *Candidate(s)* and use Add Factor > to move it to the list of *Co-predictor(s)*

To access the advanced options, select **Model...** The resulting dialog (not shown) enables the inclusion of interactions between predictors and co-predictors in the regression model. The **Results...** button invokes the dialog through which additional output (Chi-square values, coefficient, degrees of freedom, model parameters, etc.) can be included in the output spreadsheet. Neither of these steps is needed in this tutorial.

Oox Regression	n of Spreadsheet 1		
Time Variable	1. Survival (years)		- 2
Event Variable	2. Event	✓ ② Event Status death	- 2
Predictor	All Response Variables		- 2
Candidate(s)		Co-predictor(s) [
Survival (years) Surv	i bus	Add Factor > 7. tumor size (mm) < Remove Factor	
or cympirniode ord		Strata (Categorical) 👔	
		Add Factor >	
		Model	Results
		OK Cance	l Apply

• Select **OK** to start the computation

Figure 6: Configuring the Cox regression dialog

The spreadsheet generated by the Cox regression procedure (Cox) is shown in Figure 7. Each row of the spreadsheet corresponds to one of the predictors (probesets). The description of the columns is provided below.

1 & 2:	Column # and Probeset ID. Identify the predictor
3:	<i>HRatio</i> (gene). Hazard ratio of the predictor in column #2
4 & 5:	LowCI(gene) and UpCI(gene). The 95% confidence
	boundaries of the hazard ratio. LowCI and HighCI are the
	lower and upper boundary, respectively.

6:	<i>p-value(gene).</i> P-value of the corresponding χ^2 -test. A low
	value in this column indicates that the predictor poses a
	large hazard or is associated with shortened survival time
7 – 10:	HRatio(co-predictor), LowCI(co-predictor), UpCI(co-
	predictor), p-value(co-predictor). Effects of the co-
	predictor on the survival time; corresponds to columns 3 –
	6. For each additional co-predictor, a similar block of
	columns is added
11:	<i>modelfit(0).</i> P-value of the test assessing the overall model
	fit, i.e, the relationship between survival time, predictors,
	and co-predictors in the model. A <i>modelfit</i> value > 0.05
	indicates a poor association between the predictor and/or

curren	an considerant jarooo											
	1. Column #	2. Probeset ID	3. HRatio(gene)	4. LowCI(gene)	5. UpCI(gene)	6. p-value(gene)	7. HRatio(tumor size (mm))	8. LowCI(tumor size (mm))	9. UpCI(tumor size (mm))	10. p-value(tumor size (mm))	11. modelfit(0)	
1.	17036	217663_at	0.00202612	3.04539e-005	0.134799	0.00378306	1.05248	1.03171	1.07368	4.93687e-007	6.23673e-007	
2.	21592	222224_at	0.00303448	5.12715e-005	0.179595	0.00535731	1.05171	1.03159	1.07222	3.11591e-007	7.84507e-007	
3.	15366	215986_at	0.0363826	0.00163349	0.810346	0.0363656	1.04793	1.02669	1.06961	7.43324e-006	5.46226e-006	
4.	9615	210123_s_at	0.0386421	0.00512911	0.291124	0.00159017	1.05556	1.03402	1.07754	2.72499e-007	2.40343e-007	
5.	6809	207276_at	0.0477627	0.000805976	2.83045	0.144175	1.05188	1.03139	1.07278	4.67564e-007	1.69315e-00	
6.	19297	219925_at	0.0490878	0.00463365	0.520025	0.0123149	1.04826	1.0276	1.06934	3.47451e-006	2.14722e-006	
7.	8068	208562_s_at	0.0594123	0.00893444	0.39508	0.00349212	1.04657	1.02583	1.06774	8.32334e-006	5.39573e-007	
8.	44089	244112_x_at	0.0597695	0.00982303	0.363675	0.00222903	1.05186	1.03112	1.07302	6.51012e-007	1.54865e-007	
9.	14760	215378_at	0.0602972	0.00984263	0.369388	0.00239011	1.04599	1.02459	1.06784	2.01125e-005	2.20505e-007	
10.	3646	204111_at	0.0683526	0.00460682	1.01416	0.0512025	1.04885	1.02838	1.06974	2.11107e-006	6.83646e-006	
11.	14113	214729 at	0.070517	0.00434987	1.14317	0.0620618	1.05026	1.02983	1.07108	9.84872e-007	8.49759e-006	

co-predictors and the survival time

Figure 7: Viewing the result of the Cox regression procedure. Each row corresponds to one predictor variable

The hazard ratio *Hratio* is also known as relative risk and is an effect size measure used to assess the direction and magnitude of the effect of a predictor variable on relative risk of the event, controlling for other predictors in the model.

For continuous predictors (such as gene expression values and tumor size), the hazard ratio is the predicted change in the hazard for a unit increase in the predictor. A hazard ratio greater than 1.0 indicates that the predictor is associated with the event (shorter survival time), hazard ratios below 1.0 are associated with the decreased hazard of the event, and a hazard ration of 1 indicates that the predictor has no effect on the survival time. Categorical predictors, on the other hand, should be interpreted relative to the reference category.

For a detailed result on one of the predicting probesets, right-click the row header and select **HTML Report**. The report will open in a browser window (Figure 8).

Partek Inc. www.partek.com

Cox Regression Result of 217663_at

Model Information								go to top		
	Test				Chi Square	DF	p-value			
Likelihood Ratio			28.	.575278		2	6.23673e-007			
Wald			31.	412603		2	1.50952e-007			
Score Rect	angular Snip		32.	678824		2	8.01463e-008			
Coefficient Information								<u>go to top</u>		
Name	DF	Estimate	Std E	rror	W (Wald Chi Square	e)	p-value (W)	Hazard Ratio		
217663_at	1	-6.201632	2.141665		8.385116		0.00378306	0.00202612		
tumor size (mm)	1	0.0511531	0.0101721		25.288328		4.93687e-007	1.052484		
Model Fit Statistics								<u>go to top</u>		
			Without Pre	Predictor(s)			With Predictor(s)			
-2logL	570.20921					541.633937				
AIC	570.20921					545.633937				
SBC	570.209214					549.648603				

Figure 8: HTML report detailing the Cox regression parameters for one of the predicting probesets

References

Miller LD, Smeds J, George J, Vega VB et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 2005 Sep 20;102(38):13550-5

Stevenson, Mark. An Introduction to Survival Analysis. Available at: http://epicentre.massey.ac.nz/Portals/0/EpiCentre/Downloads/Personnel/MarkStevenson/ Stevenson survival analysis 241109.pdf

End of Tutorial

This is the end of the tutorial. If you need additional assistance with this data set, you may call our technical support staff at +1-314-878-2329 or email *support@partek.com*.

a. b.

Last revision: September 5, 2012

Copyright © 2012 by Partek Incorporated. All Rights Reserved. Reproduction of this material without express written consent from Partek Incorporated is strictly prohibited.

Survival Analysis in Partek® Genomics Suite[™] 6.6

July 19 2012 02:46:25 pm